756751-75-4 Usage
Uses
Used in Pharmaceutical Research:
1-(3-BENZYLOXY-PHENYL)-PIPERAZINE is used as a building block in medicinal chemistry and pharmaceutical research for the synthesis of various bioactive molecules and drugs. Its unique structure allows for the development of compounds with potential therapeutic applications.
Used in Neurological and Psychiatric Disorders Treatment:
1-(3-BENZYLOXY-PHENYL)-PIPERAZINE is used as a serotonin receptor ligand for the treatment of various neurological and psychiatric disorders. Its interaction with serotonin receptors may contribute to the modulation of neurotransmission, offering potential benefits in managing symptoms associated with these conditions.
Used in Medicinal Chemistry:
1-(3-BENZYLOXY-PHENYL)-PIPERAZINE is used as an intermediate in the synthesis of compounds with potential therapeutic applications in medicinal chemistry. Its aromatic piperazine structure provides a versatile platform for the development of new drugs targeting a range of diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 756751-75-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,5,6,7,5 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 756751-75:
(8*7)+(7*5)+(6*6)+(5*7)+(4*5)+(3*1)+(2*7)+(1*5)=204
204 % 10 = 4
So 756751-75-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H20N2O/c1-2-5-15(6-3-1)14-20-17-8-4-7-16(13-17)19-11-9-18-10-12-19/h1-8,13,18H,9-12,14H2
756751-75-4Relevant articles and documents
Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents
Abram, Micha?,Kamiński, Krzysztof,Kamiński, Rafa? M.,Latacz, Gniewomir,Lubelska, Annamaria,Mogilski, Szczepan,Rapacz, Anna
, p. 1996 - 2008 (2020/07/14)
We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.
